Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Diabetic Retinopathy

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Diabetic Retinopathy in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wu, J1
Ke, X1
Fu, W1
Gao, X1
Zhang, H1
Wang, W1
Ma, N1
Zhao, M1
Hao, X1
Zhang, Z1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Diabetic Retinopathy

ArticleYear
Inhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1α/VEGF Signaling Pathway.
    Molecules (Basel, Switzerland), 2016, Dec-21, Volume: 21, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Cell Line; Cobalt; Diabetic Retinopathy; Disease Mod

2016